Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Novogen — Investor Presentation (October 2016)
13 slides from Kazia Therapeutics's investor presentation, Oct 31, 2016
Slide 1: Novogen Limited Investor Presentation
NOVOGEN Novogen Limited Investor Presentation In-licensing of phase II ready molecule (GDC-0084) from Genentech for treatment of brain cancer (Glioblastoma) 31st October 2016 Version 1.0
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Novogen now has a diversified portfolio and is positioned for growth
Novogen now has a diversified portfolio and is positioned for growth • Focus on unmet need: pipeline of novel therapies, targeting oncology patients, poorly served by existing treatment options • Building a sustainable model: leveraging oncology expertise, developing commercially attractive, in-hous
Slide 4: Novogen is listed on ASX and NASDAQ and is well-funded for current operations
Novogen is listed on ASX and NASDAQ (via ADRs) and is well-funded for current operations Share Price (US$) 3.00 NVGN NASDAQ Biotech Index 2.50 2.00 1.50 1.00 Volume 0.50 0.00 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Market Capitalisation*A$ 41 million Listing ASX: NRT NASDAQ: NVGN (1:
Slide 5: In-licensing of GDC-0084, a promising phase II-ready drug candidate for brain cancer
In-licensing of GDC-0084, a promising phase II-ready, well-differentiated drug candidate for the treatment of advanced brain cancer • GDC-0084 has been in-licensed from Genentech • Being developed to treat the most common form of primary brain cancer, Glioblastoma Multiforme (GBM) • Pan-PI3 Kinase i
Slide 6: GDC-0084: transaction deal terms
GDC-0084: transaction deal terms • Exclusive worldwide development and commercialisation agreement for all uses • US $5M upfront, payable at time of contract signing • Performance-related consideration linked to regulatory and commercial outcomes • Royalty payments as a percentage of net sales, in-l
Slide 7: GDC-0084 has successfully completed a phase I study
GDC-0084 has successfully completed a phase I study which established dose and safety profile Phase I Study • 47 patients enrolled at 4 centres (MD Anderson, UCLA, Dana-Farber, and Vall d’Hebron) • Patients were grade 3 or 4 gliomas with at least one (and in most cases, several) lines of prior thera
Slide 8: Strong strategic rationale for in-licensing GDC-0084
Strong strategic rationale for in-licensing GDC-0084 Novogen’s strategy includes • GDC-0084 is highly complementary to existing pipeline augmentation of our pipeline • Validated mechanism (1x commercial product) and clinical data through prudent in-licensing • Strengthens Novogen’s position as an in
Slide 9: Novogen is oncology-focused, with a robust in-house pipeline and strong partnering aspirations
Novogen is oncology-focused, with a robust in-house pipeline and strong partnering aspirations Assets from internal discovery engines Programs taken through Molecules partnered with preclinical and clinical pharma / large biotech for development, generally to phase III development and completion of
Slide 10: Post transaction pipeline
Post transaction pipeline Lead Preclinical IND-Enabling Phase I Phase II Optimisation Proof-of-Concept Tox & CMC Clinical Trials Clinical Trials PI3K GDC-0084 Glioblastoma Phase II 2017 SBP TRXE-002-1 Ovarian Cancer Phase I 4Q 2016 ATM ATM-3507 Solid Tumours IND 2017 SBP TRXE-009 Solid Tumours PI3K
Slide 11: Novogen anticipates a rich news flow of value-driving events over the next 12-18 months
Novogen anticipates a rich news flow of value-driving events over the next 12-18 months Key Milestones 1Q 2016 Granting of patent for SBP technology ? 2Q 2016 Granting of patent for ATM technology ? 3Q 2016 Submission of IND for Cantrixil ? 4Q 2016 In-licensing of GDC-0084 ? Start of phase I trial f
Slide 12: Recap: diversified portfolio, positioned for growth
Recap: diversified portfolio, positioned for growth • Focus on unmet need: pipeline of novel therapies, targeting oncology patients, poorly served by existing treatment options • Building a sustainable model: leveraging oncology expertise, developing commercially attractive, in-house and external as
Slide 13: NOVOGEN
NOVOGEN